We have located links that may give you full text access.
Class I Obesity Delays Achievement of Patient Acceptable Symptom State but not Minimum Clinically Important Difference or Substantial Clinical Benefit After Primary Hip Arthroscopy for Femoroacetabular Impingement Syndrome.
Arthroscopy 2023 Februrary 20
PURPOSE: The aim of our study was to identify differences in the time taken to achieve the minimum clinically-important difference (MCID), substantial clinical benefit (SCB), and patient acceptable symptom state (PASS) following primary hip arthroscopy for treatment of femoroacetabular impingement syndrome (FAIS) among patients of different body mass index (BMI) categories.
METHODS: We conducted a retrospective comparative study of hip arthroscopy patients with minimum 2-year follow-up. BMI categories were defined as normal (18.5≤BMI<25.0), overweight (25.0≤ BMI<30.0), or class I obese (30.0≤BMI<35.0). All subjects completed the modified Harris Hip Score (mHHS) prior to surgery and at 6 months, 1 year, and 2 years postoperative. MCID and SCB cutoffs were defined as pre-to-postoperative increases in mHHS by ≥8.2 and ≥19.8, respectively. PASS cutoff was set at postoperative mHHS ≥74. Time to achievement of each milestone was compared using the interval-censored EMICM algorithm. The effect of BMI was adjusted for age and sex using an interval-censored proportional hazards model.
RESULTS: 285 patients were included in the analysis: 150 (52.6%) normal BMI, 99 (34.7%) overweight, and 36 (12.6%) obese. Obese patients had lower mHHS at baseline (p=0.006) and at 2-year follow-up (p=0.008). There were no significant inter-group differences in time to achievement for MCID (p=0.92) or SCB (p=0.69), but obese patients had longer time to PASS than normal BMI patients (p=0.047). Multivariable analysis found obesity to be predictive of longer time to PASS (HR=0.55, p=0.007) but not MCID (HR=0.91, p=0.68) or SCB (HR=1.06, p=0.30).
CONCLUSIONS: Class I obesity is associated with delays in achieving a literature-defined PASS threshold after primary hip arthroscopy for FAIS. However, future research should consider incorporating PASS anchor questions to determine whether obesity truly carries a risk of delayed achievement of a satisfactory state of health as it pertains to the hip.
METHODS: We conducted a retrospective comparative study of hip arthroscopy patients with minimum 2-year follow-up. BMI categories were defined as normal (18.5≤BMI<25.0), overweight (25.0≤ BMI<30.0), or class I obese (30.0≤BMI<35.0). All subjects completed the modified Harris Hip Score (mHHS) prior to surgery and at 6 months, 1 year, and 2 years postoperative. MCID and SCB cutoffs were defined as pre-to-postoperative increases in mHHS by ≥8.2 and ≥19.8, respectively. PASS cutoff was set at postoperative mHHS ≥74. Time to achievement of each milestone was compared using the interval-censored EMICM algorithm. The effect of BMI was adjusted for age and sex using an interval-censored proportional hazards model.
RESULTS: 285 patients were included in the analysis: 150 (52.6%) normal BMI, 99 (34.7%) overweight, and 36 (12.6%) obese. Obese patients had lower mHHS at baseline (p=0.006) and at 2-year follow-up (p=0.008). There were no significant inter-group differences in time to achievement for MCID (p=0.92) or SCB (p=0.69), but obese patients had longer time to PASS than normal BMI patients (p=0.047). Multivariable analysis found obesity to be predictive of longer time to PASS (HR=0.55, p=0.007) but not MCID (HR=0.91, p=0.68) or SCB (HR=1.06, p=0.30).
CONCLUSIONS: Class I obesity is associated with delays in achieving a literature-defined PASS threshold after primary hip arthroscopy for FAIS. However, future research should consider incorporating PASS anchor questions to determine whether obesity truly carries a risk of delayed achievement of a satisfactory state of health as it pertains to the hip.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app